Innate Pharma SA IPHA 深 沪
已收盘 05-08 16:00:00 美东时间
1.41
+0.040
+2.92%
华盛通- 最 高1.49
- 今 开1.44
- 成交量 6801股
- 最 低 1.40
- 昨 收 1.37
- 总市值 1.32亿
- 52周最高 2.63
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.17
- 委 比 55.31%
- 总股本 9382.92万
- 历史最高 11.95
- 量 比 0.29
- 振 幅 6.57%
- 历史最低 1.17
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026
Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy in resectable
04-18 03:01
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.
04-08 01:45
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 1.69 percent increase over losses of $(0.65) per share from the
03-26 14:14
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8
BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.
03-12 18:58
Innate Pharma to Join Leerink Partners Global Healthcare Conference in Miami
Innate Pharma to Join Leerink Partners Global Healthcare Conference in Miami Innate Pharma SA will participate in the Leerink Partners Global Healthcare Conference 2026, held in Miami, Florida, from March 8-11, 2026. The company’s executive team will join a fireside chat on March 9, 2026, at 3:40 PM
02-18 14:00
FDA Clears Innate Pharma to Begin Phase 3 Trial of Lacutamab in CTCL
Innate Pharma SA has announced that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with the TELLOMAK 3 confirmatory Phase 3 trial of lacutamab in cutaneous T-cell lymph...
2025-11-10 14:00
Innate Pharma Schedules Q3 2025 Results Conference Call
The latest announcement is out from Innate Pharma SA ( ($FR:IPH) ). On November...
2025-11-05 19:27
